Safety and Efficacy of Abaloparatide-SC in Men With Osteoporosis (ATOM)
A Randomized, Double-blind, Placebo-controlled, Phase 3 Multicenter Study to Evaluate the Safety and Efficacy of Abaloparatide-SC for the Treatment of Men With Osteoporosis
Sponsor: Radius Health, Inc.
This PHASE3 trial investigates Age Related Osteoporosis and Osteoporosis and is currently completed. Radius Health, Inc. leads this study, which shows 13 recorded versions since 2018 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
May 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Dec 2021 — May 2023 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
▶ Show 8 earlier versions
-
Sep 2021 — Dec 2021 [monthly]
Active Not Recruiting PHASE3
-
Jan 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE3
-
Oct 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
May 2020 — Oct 2020 [monthly]
Recruiting PHASE3
-
Apr 2020 — May 2020 [monthly]
Recruiting PHASE3
-
Feb 2019 — Apr 2020 [monthly]
Recruiting PHASE3
-
Jun 2018 — Feb 2019 [monthly]
Recruiting PHASE3
-
May 2018 — Jun 2018 [monthly]
Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Radius Health, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .